<DOC>
	<DOCNO>NCT00676884</DOCNO>
	<brief_summary>The primary objective study investigate effect AERODERM ( also know pitrakinra , AER 001 , BAY 16-9996 ) Eczema Area Severity Index ( EASI ) score subject moderate severe atopic eczema</brief_summary>
	<brief_title>A Phase 2a Study Investigate Effects Repeated Administration AeroDerm Subjects With Atopic Eczema</brief_title>
	<detailed_description>The primary objective study investigate effect AERODERM ( also know pitrakinra , AER 001 , BAY 16-9996 ) Eczema Area Severity Index ( EASI ) score subject moderate severe atopic eczema randomise , placebo control , parallel-group study bid sc . dose AERODERM 28 day</detailed_description>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Adult male female &gt; 18 year . Subjects currently allergic eczema EASI score range 1050 . Subjects stable dose topical medication eczema â‰¥ 1 month screen whose eczema adequately responsive , control , conventional topical treatment ( eg : topical steroid , Tracrolimus , Pimecrolimus ) . Subjects systemic immunosuppressive therapy ( eg systemic steroid ) within 1 month screening . Subjects female , currently pregnant breast feed use medically acceptable method contraception . Subjects prestudy medical history , physical examination vital sign acceptable investigator . Subjects clinical laboratory test within reference range clinically acceptable investigator . Subjects negative HbsAg , hepatitis C antibody HIV II I test screen . Subjects negative drug abuse test screen admission . Subjects stable , adequately treat medical condition eczema may enrol provide Investigator consider study participation place increase risk adverse event . Subjects continue concomitant treatment medical condition ( eczema ) . Subjects able willing give write informed consent . Subjects conform inclusion criterion . Subjects follow medical condition : Diabetes mellitus , Thyroiditis , Rheumatiod arthritis , Multiple sclerosis , Uveitis , Sarcoidosis , Glomerulonephritis , Helminthic infection . Subjects history relevant drug hypersensitivity . Subjects history alcoholism . Subjects history drug abuse . Subjects significant infection time screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) , may ask reschedule screen and/or admission longer acute symptom . Subjects acute infection influenza time screen and/or admission . Female subject use acceptable method contraception . Subjects use investigational drug /or participate clinical trial within 3 month first dose . Subjects previously receive AeroDerm . Subjects use medication , opinion Investigator affect outcome study . Subjects donate and/or receive blood blood product within previous 3 month prior first dose ( review case case basis ) . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>atopic eczema</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>allergy</keyword>
</DOC>